| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3193643 | Annals of Allergy, Asthma & Immunology | 2006 | 4 Pages |
Abstract
Our experience suggests that some patients with anaphylactoid reactions to omalizumab can tolerate the medication when pretreated with nonsteroidal anti-inflammatory drugs but that a serum sickness-like illness may develop, requiring discontinued use of the medication.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
David H. MD, PhD, Christopher C. MD,